HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice.
about
Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosisMyeloid cell transmigration across the CNS vasculature triggers IL-1β-driven neuroinflammation during autoimmune encephalomyelitis in mice.Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes.Interleukin-1β and interleukin-1 receptor antagonist appear in grey matter additionally to white matter lesions during experimental multiple sclerosisExperimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS).Gemfibrozil, a lipid-lowering drug, upregulates IL-1 receptor antagonist in mouse cortical neurons: implications for neuronal self-defenseThe Interleukin-1 Balance During Encephalitis Is Associated With Clinical Severity, Blood-Brain Barrier Permeability, Neuroimaging Changes, and Disease Outcome.Expression of IL-1β in rhesus EAE and MS lesions is mainly induced in the CNS itself.Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis.HSV Recombinant Vectors for Gene Therapy.New Insights into the Role of IL-1β in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.Future viral vectors for the delivery of asymptomatic herpes epitope-based immunotherapeutic vaccines.IL-1R signaling within the central nervous system regulates CXCL12 expression at the blood-brain barrier and disease severity during experimental autoimmune encephalomyelitis.Endothelial IL-1R1 is a critical mediator of EAE pathogenesisTreatment of experimental autoimmune encephalomyelitis in SJL/J mice with a replicative HSV-1 vector expressing interleukin-5.The virtues and vices of harnessing HSV vectors for CNS autoimmunity modulation.Anti-inflammatory effect by lentiviral-mediated overexpression of IL-10 or IL-1 receptor antagonist in rat glial cells and macrophages.Interleukin-1β promotes long-term potentiation in patients with multiple sclerosis.Amyloid-β Homeostasis Bridges Inflammation, Synaptic Plasticity Deficits and Cognitive Dysfunction in Multiple Sclerosis.
P2860
Q28740839-84274CE1-5BEF-4B66-B3EA-C5C275E60B94Q30763241-897C62D6-7184-410F-AEE1-A0EE93650424Q34200072-C0CF10C1-6AAC-40A4-8AB4-3675EF1E15D3Q35078252-B952FA4B-5156-463E-A2BB-AC4C560C0EF5Q35589934-D17B4BCD-E7E7-4641-8900-4DA8CE80A8D8Q36469000-9D420459-A51F-4927-A198-B7E4B706D6E6Q36816593-CF570B20-7EFC-49E2-B336-ED0A72DE49E9Q36976299-79A869D9-12E6-4811-97D1-83B1495A1EB4Q37114231-3C3FBE74-EDBA-4C7D-9E00-5635552A94E0Q37787777-6B2250B2-D254-415E-BDFC-F6D8963C21FAQ39353100-AF21EE98-6EEF-4761-9C9C-403B35F4BAC3Q39767193-5ACBDB7F-1B48-4E64-8675-5263E25B7DB6Q41480082-5122CBDF-F63D-44A3-9907-D9E573761899Q41526568-4D14CEF1-82BB-4ACF-8DB0-461BD2EDF4F8Q43735065-121A7E74-8CA7-42C2-821C-04F14DB29CD5Q43749965-E2290D16-78FD-40FC-8E1E-B57271E96EE7Q45857204-B8671046-A7BA-4326-962F-3601822B8D97Q46899417-D764F5AE-7B70-48A9-9E6E-3839EC2DBAEFQ47117780-249B0E58-F519-4CB3-9DD1-2C96D1AEFD5A
P2860
HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG
@nl
HSV-1-mediated IL-1 receptor a ...... phalomyelitis in C57BL/6 mice.
@en
type
label
HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG
@nl
HSV-1-mediated IL-1 receptor a ...... phalomyelitis in C57BL/6 mice.
@en
prefLabel
HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG
@nl
HSV-1-mediated IL-1 receptor a ...... phalomyelitis in C57BL/6 mice.
@en
P2093
P2860
P50
P356
P1433
P1476
HSV-1-mediated IL-1 receptor a ...... ephalomyelitis in C57BL/6 mice
@en
P2093
P2860
P2888
P356
10.1038/SJ.GT.3302805
P577
2006-08-24T00:00:00Z